Efgartigimod

Last Updated: 04/28/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 358 publications

Identification of immunomodulators associated with atrial fibrillation reporting to better understand AF immunologic mechanisms: a Vigibase retrospective disproportionality analysis and a literature review.

Identification of immunomodulators associated with atrial fibrillation reporting to better understand AF immunologic mechanisms: a Vigibase retrospective disproportionality analysis and a literature review.

Journal: BMJ open
Published: April 07, 2026

Real-World Application of Subcutaneous Efgartigimod in Chronic Inflammatory Demyelinating Polyradiculoneuropathy.

Real-World Application of Subcutaneous Efgartigimod in Chronic Inflammatory Demyelinating Polyradiculoneuropathy.

Journal: Internal medicine (Tokyo, Japan)
Published: March 18, 2026

Correction: Assessing the Value Contribution of Vyvgart® (Efgartigimod Alfa) in the Treatment of Generalized Myasthenia Gravis with Acetylcholine Receptor Antibody in Spain Through Multi-criteria Decision Analysis.

Correction: Assessing the Value Contribution of Vyvgart® (Efgartigimod Alfa) in the Treatment of Generalized Myasthenia Gravis with Acetylcholine Receptor Antibody in Spain Through Multi-criteria Decision Analysis.

Journal: Advances in therapy
Published: March 12, 2026

Efficacy and Safety of Subcutaneous Efgartigimod PH20 in Adults With Primary Immune Thrombocytopenia (ADVANCE SC): A Multicenter, Randomized, Double-Blinded, Placebo-Controlled, Phase 3 Trial.

Efficacy and Safety of Subcutaneous Efgartigimod PH20 in Adults With Primary Immune Thrombocytopenia (ADVANCE SC): A Multicenter, Randomized, Double-Blinded, Placebo-Controlled, Phase 3 Trial.

Journal: American journal of hematology
Published: March 09, 2026

Real-World Evaluation of Efgartigimod in Generalized Myasthenia Gravis: A Single-Center Experience.

Real-World Evaluation of Efgartigimod in Generalized Myasthenia Gravis: A Single-Center Experience.

Journal: Journal of clinical neuromuscular disease
Published: March 02, 2026

Opposing effects of efgartigimod and rozanolixizumab on serum albumin levels in patients with generalized myasthenia gravis.

Opposing effects of efgartigimod and rozanolixizumab on serum albumin levels in patients with generalized myasthenia gravis.

Journal: Naunyn-Schmiedeberg's archives of pharmacology
Published: February 17, 2026

Influence of Efgartigimod on Curative Efficacy and Inflammation Factors of Patients with Long Segmental Myelitis.

Influence of Efgartigimod on Curative Efficacy and Inflammation Factors of Patients with Long Segmental Myelitis.

Journal: Journal of visualized experiments : JoVE
Published: January 26, 2026

Efgartigimod for Fetal Acetylcholine Receptor Antibody-Related Disorder.

Efgartigimod for Fetal Acetylcholine Receptor Antibody-Related Disorder.

Journal: The New England journal of medicine
Published: January 21, 2026

Case Report: Dual response to efgartigimod in myasthenia gravis and comorbid autoimmune disorders: a case series.

Case Report: Dual response to efgartigimod in myasthenia gravis and comorbid autoimmune disorders: a case series.

Journal: Frontiers in immunology
Published: January 15, 2026

Immunotherapies in chronic immune-mediated neuropathies.

Immunotherapies in chronic immune-mediated neuropathies.

Journal: Handbook of clinical neurology
Published: January 12, 2026

Health economic evaluations of myasthenia gravis: a systematic review.

Health economic evaluations of myasthenia gravis: a systematic review.

Journal: Croatian medical journal
Published: January 11, 2026

Novel Therapies for Generalized Myasthenia Gravis: Insights Into FcRn and Complement Inhibition.

Novel Therapies for Generalized Myasthenia Gravis: Insights Into FcRn and Complement Inhibition.

Journal: American journal of therapeutics
Published: January 08, 2026
Showing 1-12 of 358

Last Updated: 04/28/2026